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We constructed a number of HXB2 viruses chimeric for the gp120 glycoprotein derived from a number of viable molecular
clones obtained from a primary isolate. Comparative biological characterization of the parental primary viruses with the
gp120.HXB2 chimeras demonstrated identical patterns of cell tropism and cytopathicity. Furthermore, both parental and
chimeric viruses were insensitive to neutralization by sCD4 and a panel of conformation-dependent monoclonal antibodies,
demonstrating that transfer of the gp120 protein alone was sufficient to confer a ‘‘neutralization-resistant’’ phenotype to
the T-cell-adapted clone HXB2. We assessed the contribution of gp120 epitopes to the neutralizing immune response by
comparing the sensitivity of these viruses to neutralization by a panel of sera from HIV-infected individuals. Seven of eleven
sera tested were able to neutralize HXB2 and two or more of the chimeric viruses; in contrast, only one serum neutralized
more than one of the parental primary virus clones. The association of gp120–gp41 envelope at the surface of infected
PBMC cultures was measured in the presence or absence of soluble CD4. No differences in CD4-induced gp120 dissociation
were seen between the chimeric and parental virus-infected cultures. Since gp120 conformation appeared the same between
primary and chimeric viruses, we suggest that the ability of human sera to neutralize the chimeric viruses may be mediated
by epitopes within gp41. q 1996 Academic Press, Inc.
INTRODUCTION that the appearance of SI virus is associated with more rapid
CD4 cell decline and onset of symptoms (Cheng-Mayer et
The majority of functional studies of the HIV-1 envelope al., 1988; Tersmette et al., 1989; von Gegerfelt et al., 1991;
glycoprotein have been carried out with laboratory-adapted Schuitemaker et al., 1992; Connor and Ho, 1994).
isolates which have been extensively propagated in T-cell Primary viruses are insensitive to neutralization by solu-
lines. However, it is now apparent that ‘‘primary’’ viruses, ble CD4 (sCD4). Several reports have suggested that this
isolated directly from patient tissue and only allowed to repli- resistance is mediated by a reduced affinity of the oligo-
cate for one to two passages in peripheral blood mononu- meric envelope complex for sCD4 (Ashkenazi et al., 1991;
clear cells (PBMC) and/or macrophages, differ from labora- Moore et al., 1992; Turner et al., 1992). Recent data suggest
tory adapted isolates in a number of important aspects. that primary viruses are resistant to neutralization by the
Some primary viruses replicate slowly and fail to induce a majority of monoclonal antibodies (mAbs) cloned from ani-
multinucleated cytopathic effect (termed slow/low and non- mals immunized with recombinant gp120. Furthermore,
syncytial inducing, NSI) whereas others replicate with faster sera from individuals immunized with recombinant gp120
kinetics and are able to induce syncytia in their target cells were generally unable to neutralize primary viruses (Moore
(termed fast/high and syncytial inducing, SI) (A˚sjo¨ et al., 1986; et al., 1995; Wrin et al., 1995). This resistance to neutraliza-
Cheng-Mayer et al., 1988; Fenyo¨ et al., 1988; Tersmette et tion both by sCD4 and mAbs may reflect a structural motif
al., 1989). Generally, NSI viruses fail to replicate in estab- common to all primary viruses. However, short-term culture
lished cell lines, whereas SI viruses replicate in a variety of of primary viruses in PBMC is likely to maintain high levels
T-lymphoid and monocytoid cell lines. Several authors have of variation and, in contrast to long-term propagation in
reported that viruses isolated from the majority of infected clonal T-cell lines, such antigenic variation may be an im-
individuals during the course of disease progression change portant factor contributing to the apparent resistance of
their in vitro properties from NSI to SI phenotype, suggesting primary viruses to neutralization by various ligands (Ham-
mond et al., 1996). However, some primary viruses are
sensitive to neutralization by a limited number of human
Sequence data from this article have been deposited with the Gen-
mAbs and polyclonal human sera (Burton et al., 1994; Con-Bank data library under Accession Nos. U57788–U57794.
ley et al., 1994; Kattinger, 1994; Kostrikis et al., 1996; Mas-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: 01734 750 140. cola et al., 1994; Moore et al., 1996; Scarlatti et al., 1993;
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Trkola et al., 1996; Weber et al., 1995). It is interesting to was amplified from a panel of l clones containing full-
length HIV genomes (Frederiksson et al., 1991) using thenote that there is little or no correlation between genotype
and neutralization type in that some viruses are sensitive primers 626 (sense, restriction enzyme site underlined)
5*-GTG GGT CAC CGT CTA TTA TTG GG and 524 (anti-to neutralization by serum from individuals infected with
viruses of diverse clades. Likewise, some individuals, in- sense) 5*-CAC CAC GCG TCT CTT TGC CTT GGT GGG
using 30 cycles of amplification (947, 40 sec; 507, 35 sec;cluding those belonging to ‘‘nonprogressor’’ cohorts (Cao
et al., 1995; Pantaleo et al., 1995), have an antibody re- 727, 210 sec) in a volume of 50 ml with template con-
taining 10 ng of proviral DNA and 16 ng of each primer,sponse that can neutralize many primary viruses. These
results clearly indicate that antibodies capable of neutraliz- 200mM concentrations of each deoxynucleotide triphos-
phate, 11 PFU buffer, and 0.5 units of PFU polymeraseing divergent primary viruses exist in response to a natural
infection. The question remains as to whether such antibod- (Stratagene). The gp160-encoding region was amplified
using the primers 626 and 945 (antisense) 5* GGT CTCies can be generated by a recombinant antigen. At present,
the epitopes recognized by such cross-neutralizing antibod- GAG GAG ATA CTG CTC CC using the same reaction
conditions. To prevent exonucleolytic degradation theies are not known; it is important that future studies be
targeted at understanding the nature of such antibodies. PCR product was frozen immediately upon completion
of the reaction. Ten microliters of the PCR reaction wasStudies to define neutralization epitopes on primary viruses
have mostly used human mAbs, the majority of which have visualized on an agarose gel and PCR products were
purified by the Geneclean procedure (Bio 101, La Jolla,failed to neutralize, despite being able to completely neu-
tralize laboratory strains of HIV in T-cell-based assays (Sulli- CA), restriction digested with either BstEII/MluI or BstEII/
XhoI, and ligated into pHXB2-MCS D env (McKeatingvan et al., 1995).
The envelope glycoprotein gp120/gp41 plays an im- et al., 1993a). Ligation mixtures were transformed into
competent Escherichia coli (TG2, New England Biolabs)portant role in determining cellular attachment, entry, cy-
topathicity, and sensitivity to neutralization by sCD4 and and individual colonies screened for inserts by PCR us-
ing primers 626/524. Plasmid preparations of clones con-mAbs. We have constructed a number of HXB2 viruses
chimeric for the gp120 glycoprotein derived from a num- taining inserts were prepared using Wizard miniprep kits
(Promega). The gp120 region of each of the l clonesber of viable molecular clones obtained from a primary
isolate (Fredriksson et al., 1991; Tan et al., 1993). Com- was sequenced with a series of primers using a cycle
sequencing protocol and an Applied Biosystems 373Aparative biological characterization of the parental pri-
mary viruses with the gp120.HXB2 chimeras demon- automated sequencer (Arnold et al., 1995).
strated identical patterns of cell tropism and cytopathi-
city. Furthermore, both the parental and chimeric viruses Transfection of l and HXB2 chimeric clones and
were insensitive to neutralization by sCD4 and a panel biological characterization of recovered virus
of gp120-specific mAbs, demonstrating that transfer of
the gp120 protein alone was sufficient to confer a ‘‘neu- All clones (5 mg of l and 2 mg of pHXB2) were
transfected into both HeLa and HeLa–CD4 cells usingtralization-resistant’’ phenotype to the T-cell-adapted
clone HXB2. In contrast, the chimeric viruses were as lipofectamine (Gibco BRL). In addition pHXB2 was also
transfected into the H9 cell line. After 72 hr thesensitive as HXB2 to neutralization by a panel of poly-
clonal human sera, suggesting that the observed neutral- transfected HeLa cells were cocultured with two million
phytohemaglutinin (PHA)-stimulated PBMC for 24 hr.ization was independent of gp120. Alternatively, associa-
tion of primary virus gp120 with HXB2 gp41 transmem- Transfected H9 cells were propagated in RPMI/10% FCS
and cell-free supernatant was collected after 7 days.brane protein may result in an altered gp120/gp41
conformation(s) affecting the presentation of epitopes to PBMC were recovered from the HeLa monolayer,
washed, and cultured in RPMI/10% FCS/IL-2 (5 u/ml) me-human serum antibodies. However, we were unable to
demonstrate any differences in gp120 conformation be- dium for 21 days with the addition of fresh uninfected
PBMC after 7 and 14 days. The extracellular fluid wastween primary and chimeric virus-infected cultures.
These data are consistent with the interpretation that tested for the presence of soluble p24 antigen as de-
scribed previously (Sundqvist et al., 1989; McKeating etcross-neutralizing antibodies present in human sera may
be targeted toward conserved epitope(s) located in gp41 al., 1993a). The transfected HeLa–CD4 cells were moni-
tored for their production of soluble and intracellular p24(Muster et al., 1993; Buchacher et al., 1994).
antigen. Cells were fixed with methanol:acetone (1:1 ra-
tio, stored at 0207) and incubated with mAbs specificMATERIALS AND METHODS
for p24 (MRC ADP repository); bound antibodies were
PCR amplification, cloning, and sequencing of gp120
detected with a b-galactosidase-conjugated anti-mouse
and gp160 sequences
Ig and X-gal as described previously (Clapham et al.,
1992). Cells expressing p24 antigen give rise to coloredThe PCR followed the protocols previously reported
(McKeating et al., 1993a). The gp120-encoding region foci, and those viruses capable of inducing cytopathic
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effects in the HeLa–CD4 cells resulted in multinucleated 1 isolate KI4803 (Frederiksson et al., 1991). Eight full-
length molecular clones were obtained, seven of whichfoci which could be quantified. Both extracellular virus
and infected PBMC were tested for their ability to initiate were shown to give rise to infectious virus after transfec-
tion into PBMC. Previously, we have reported phenotypicinfection with a panel of T-cell lines, including MT2,
SupT1, CEM, and U937 cells (Fenyo¨ et al., 1988; Boucher variation among the seven clones (Tan et al., 1993) and
were therefore interested in determining the level of en-et al., 1992). T-cell lines were monitored for signs of
cytopathic effect and for the production of p24 antigen. velope variation present. The gp120-encoding region
was sequenced for each clone, and the amino acid trans-Cell-free supernatants were collected from PBMC cul-
tures and assessed for the levels of infectious virus by lation of these sequences is shown in Fig. 1. The average
pairwise distance between the clones was 3.4% (range,determining the 50% infectious dose (ID50) for PBMC.
Infection was measured by the detection of p24 antigen 1.6–5.4%) with an average Dn/Ds ratio of 1.51 (range,
0.62–2.21) (Nei and Gojobori, 1986). The majority of(Sundqvist et al., 1989; McKeating et al., 1993a). ID50 val-
ues were determined by the Kaerber formula. amino acid substitutions was conservative and was
found in both the previously defined variable and the
Neutralization assay conserved regions (Modrow et al., 1987). The V2 and V3–
Neutralization was assessed using PHA-stimulated C3 regions were the most polymorphic; however, some
PBMC as target cells with determination of p24 antigen substitutions were observed in all regions. In addition,
production as the endpoint as reported previously (von length differences in the V1, V2, and V5 regions were
Gegerfelt et al., 1991; Scarlatti et al., 1993; Albert et al., seen, and these did not result in frameshift mutations.
1990). A panel of sera were chosen at random from
asymptomatic HIV-1-infected individuals. Serum or mAb Biological characterization of parental and chimeric
dilutions, 75 ml, were incubated at 377 (1 hr) with an viruses
equal volume of virus (in duplicate using three different
dilutions, 1:5, 1:25, and 1:125). Following the virus/anti- In order to study the biological effects of the different
body incubation 100,000 PBMC in a final volume of 75 envelope genes, in isolation from the rest of the l ge-
ml RPMI, 10% FCS, IL-2 (5 u/ml), mixed from two blood nome, we transferred both the gp120- and the gp160-
donors, were added. PBMC were washed on Days 1 and encoding regions into the molecular clone pHXB2-MCS
3, such that cells were pelleted by centrifugation and the (McKeating et al., 1993a). The cloning sites transferred
medium was changed (Albert et al., 1993). The ID50 of the gp120 region from amino acid 38 (7 amino acids after
the virus stock was determined in parallel and the neu- the end of the signal peptide) to 6 amino acids prior
tralization assay was evaluated for virus dilutions con- to the gp120/gp41 cleavage signal. The same amino-
taining 10–75 ID50 . Neutralization was defined as the terminal cloning site was used to clone the gp160 gene,
ability of a serum to completely inhibit virus replication together with the first 17 amino acids of nef. The frag-
as assessed by p24 antigen production, that is, an ab- ments cloned were generated by PCR and therefore repli-
sorbance value below the cutoff value for the antigen cate clones were analyzed in order to reduce the possi-
ELISA of 100 pg. bility of PCR-induced error. Transfection of HXB2, l, and
chimeric clones into both HeLa and HeLa–CD4 cellsGp120 quantification and ligand binding studies:
gave rise to virions that were capable of replicating inELISA
PBMC (Table 1). Transfected HeLa–CD4 cells were
Extracellualr media from infected cultures were inacti- screened for virus replication both by assays of extracel-
vated with 1% NP-40, which does not irreversibly dena- lular p24 antigen and by the detection of intracellular p24
ture gp120/gp160 (McKeating et al., 1993a), and the con- antigen producing foci. All clones gave rise to multinucle-
centration of gp120 present was determined by ELISA, ated foci (Table 1). We previously reported that l clone
as previously described using recombinant gp120 as a 33 was nonviable (Frederiksson et al., 1991); however,
reference standard (Moore et al., 1992). For ligand bind- sequence analysis showed that this clone has a full
ing studies, detergent-solubilized gp120 was allowed to gp120 open reading frame (Fig. 1). Moreover, the chime-
bind to the solid phase via the polyclonal antiserum ric HXB2.gp120 clone expressing this envelope was via-
D7324 (Aalto Bioreagents, Dublin, Ireland) at an input ble (Table 1), suggesting that any defect(s) is located
concentration of 50 ng/ml. The ability of mAbs and sCD4 elsewhere in the genome. Transfected HeLa cells were
to bind to the captured gp120 was assessed by pre- cocultured with PBMC for 24 hr. All viruses replicated in
viously published methods (Moore et al., 1990). PBMC, resulting in comparable levels of p24 antigen (Ta-
ble 1). Production of infectious virus, as measured by theRESULTS
ID50 , was reduced for all HXB2.gp120 chimeric viruses
Sequence analysis of KI4803 l clones compared to the l clones. However, both HXB2 and the
gp160 chimeras (l2 and 31) replicated poorly in PBMC,A l library was constructed from the genomic DNA
obtained from a short-term PBMC culture (7 days) of HIV- resulting in low levels of infectious virus (Table 1). These
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FIG. 1. Peptide translation of gp120 sequences from KI4803 l clones. The consensus is shown above the alignment, identity is indicated by a
dot, departures from the consensus are indicated by the single letter amino acid codes, and ‘‘-’’ indicates that an amino acid is missing. The
sequence of the HXB2 gp120 is indicated for comparative purposes.
data suggest that the envelope glycoprotein is one of the cells, resulting in infectious titers greater than 75 ID50/ml.
However, HXB2 replicated preferentially in C8166 cells,determinants of replication rate in PBMC cultures.
We have previously reported differences in the cell yielding a titer of 380 ID50/ml compared to 50 and 5
ID50/ml in SupT1 and PBMC cultures, respectively.tropism of virus derived from the l clones (Tan et al.,
1993). We therefore tested the ability of a number of Epitopes capable of inducing neutralizing antibodies
have been mapped to both gp120 and gp41 (reviewedviruses chimeric for gp120 to replicate in a range of T-
cell lines. Infected PBMC were cocultivated with MT2, in Steimer et al., 1991). In order to study the relative
contribution of gp120 epitopes to the overall immuneSupT1, U937, and CEM cells in the absence of IL-2 and
were monitored both for cytopathic effect and for the response we compared the sensitivity of HXB2, primary
l, and a number of chimeric viruses to neutralization byproduction of p24 antigen (Table 2A). Syncytia were ob-
served in both MT2 and SupT1 cells with all of the clones a panel of sera from HIV-infected individuals (Table 3A).
Since HXB2 failed to produce detectable levels of extra-tested; similarly, p24 antigen was detected in all of
these cultures. In contrast, only HXB2, l32, and cellular virus in the PBMC cultures, we transfected H9
cells to obtain HXB2 sufficient for neutralization studies.HXB2.gp120l32 were able to replicate in U937 and CEM
cells (Table 2A). These observations demonstrate that We (data not shown) and others (Wrin et al., 1995) have
demonstrated that the sensitivity of a virus to neutraliza-the ability of a virus to replicate in both U937 and CEM
cells is determined by gp120 and that the gp120 chimeric tion is the same irrespective of the cell used for propaga-
tion. This is in contrast to that reported by Sawyer andviruses are phenotypically similar to the l clones from
which they derive with respect to their patterns of cell colleagues (1994) who stated that several passages of
a virus through a cell line were required to observe differ-tropism. Extracellular virus from transfected HeLa–CD4
cells was assessed for its ability to infect both PBMC ences in neutralization sensitivity suggesting viral adap-
tation. However, we only propagated HXB2 in H9 cellsand the T-cell lines C8166 and SupT1 (Table 2B). All of
the chimeric viruses replicated in the PBMC and SupT1 for 7 days. Seven of the eleven sera tested were able to
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TABLE 1 number of gp120-specific, conformation-dependent li-
gands to neutralize HXB2, l, and chimeric viruses (TableTransfection of HXB2, l Clones, and gp120 and gp160 Chimeras
3B). sCD4, three mAbs mapping to the discontinuous
p24 antigen CD4 b.s. (1.5e, 2.1H, and 39.13g) (Cordell et al., 1991; Ho
(ng/ml) et al., 1991), and two mAbs mapping to linear determi-
Cytopathicity ID50 nants within V2 (10/76b, 12b) (McKeating et al., 1993b;
Clone in HeLa– CD4 Helaa PBMCb PBMCc
Shotton et al., 1995) together with mAb 268-D, specific
for a linear epitope within V3 (Gorny et al., 1989), at alCL2 / ud 2.4 280
lCL13 / ud 1.8 75 final concentration of 20 mg/ml, failed to neutralize any
lCL31 // ud 2.8 440 of the viruses expressing primary glycoproteins, whereas
lCL32 // ud 3.1 310 all of these ligands, with the exception of 268-D, were
lCL82 / ND 2.1 280
able to neutralize HXB2. In contrast, mAb 2G12, mapping
HXB2 // 1.1 1.6 5 to a discontinuous epitope distinct from the CD4 binding
HXB2.gp120CL2 / 1.1 3.2 125 site (Buchacher et al., 1994), was able to neutralize all
HXB2.gp120CL13 / 4.5 2.8 75
of the viruses. A control mAb, 2F5, specific for a linearHXB2.gp120CL31 // 4.8 3.4 185
epitope in gp41 (Muster et al., 1993; Buchacher et al.,HXB2.gp120CL32 // 4.8 3.4 ND
HXB2.gp120CL33 / 3.6 3.1 ND 1994; Conley et al., 1994b) neutralized HXB2, all of the
HXB2.gp120CL82 / 5.0 4.3 100 chimeric viruses, and two of the four l viruses (Table
3B). These data fail to show any differences in the gp120HXB2.gp160CL2 / 1.0 1.6 5
conformation between the l and chimeric viruses.HXB2.gp160CL31 / 0.9 1.4 5
The inability of the gp120-specific mAbs to neutralize
Note. HXB2, l, and chimeric plasmid DNA were transfected into both the l and the chimeric viruses could be attributable
HeLa and HeLa–CD4 cells and monitored for signs of infection. Soluble to antigenic variation. To test this possibility we followed
p24 antigen was measured in the HeLaa cells 48 hr posttransfection.
the ability of the mAbs to bind to detergent-solubilizedTransfected HeLa cells were cocultuivated with PBMC for 24 hr and
gp120 obtained from the same viral stocks as used forthe nonadherent PBMC maintained for 21 days in culture. PBMC cul-
tures were assessed both for soluble p24 antigenb and infectious virusc the neutralization studies. Levels of gp120 present in the
(ID50/75 ml) 7 days postinfection. ud, undetectable levels of p24 antigen; viral lysates were quantified in an ELISA using a pool
ND, not done. of sera from HIV-infected individuals as the detecting
antibody (Table 4). All of the viral lysates bound sCD4
neutralize HXB2 and two or more of the chimeric viruses; with comparable efficiencies. MAbs, 39.13g and 1.5e,
in contrast, only one serum (no. 3) neutralized more than mapping to the CD4 b.s., bound to l31, 32, and HXB2,
one of the l clones. The ability of the sera to neutralize but showed no recognition of l2 and 13. In addition,
the gp120 chimeric viruses could be mediated via epi- both l2 and 13 bound with low OD values to mAb 2.1h,
topes outside gp120; alternatively, the interaction of suggesting that this group of mAbs recognizes distinct
l.gp120 with HXB2 gp41 could result in a novel confor- epitopes within the CD4 binding region. In contrast,
mation(s) unique to the chimeric molecule. In order to mAbs 268-D and 2G12 bound all the l proteins, though
with reduced OD values for both l2 and 13. HXB2 failedtest the latter hypothesis we measured the ability of a
TABLE 2A
Comparative Replication of HXB2, l and gp120 Chimeric Viruses in T-Cell Lines: Cell–Cell Coculture
p24 (ng/ml) 3 days p.i. in p24 (ng/ml) 8 days p.i. in
Clone MT-2 SupT1 U937-2 CEM MT-2 SupT1 U937-2 CEM
lCL2 24.2 6.0 ud ud 50.0 50.0 ud ud
lCL13 48.4 42.5 ud ud 50.0 50.0 ud ud
lCL31 18.2 3.0 ud ud 50.0 50.0 ud ud
lCL32 45.6 22.5 15.3 15.4 50.0 50.0 50.0 50.0
lCL82 24.9 11.2 ud ud 50.0 50.0 ud ud
HXB2 46.3 48.5 6.5 4.5 50.0 50.0 45.2 39.5
HXB2.gp120CL2 21.4 12.5 ud ud 50.0 50.0 ud ud
HXB2.gp120CL13 46.3 39.5 ud ud 50.0 50.0 ud ud
HXB2.gp120CL31 40.5 46.7 ud ud 50.0 50.0 ud ud
HXB2.gp120CL32 44.2 46.3 12.4 6.5 50.0 50.0 50.0 50.0
HXB2.gp120CL82 39.5 42.1 ud ud 50.0 50.0 ud ud
Note. ud, undetectable levels of p24 antigen (75 pg/ml).
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TABLE 2B DISCUSSION
Comparative Replication of HXB2 and gp120 Chimeric Viruses These experiments demonstrate that it is possible to
in T-Cell Lines: Cell-Free Infection construct chimeric viruses expressing primary gp120 en-
velope proteins. The viability of such viruses is consistent
Infectious titer (ID50)/0.075 ml for cells
with the functional conservation of the gp120 amino- and
carboxy-termini, which are reported to be essential forClone C8166 SupT1 PBMC
association with the transmembrane glycoprotein gp41
HXB2 380 50 5 (Helseth et al., 1991; Schulz et al., 1992). No variability
HXB2.gp120CL2 5 120 80 was detected in the amino-terminus (aa 1–31) and only
HXB2.gp120CL13 15 140 75
five substitutions were detected in the carboxyl C5 do-HXB2.gp120CL31 5 135 85
main (aa 410–465 of HXB2, Fig. 1). This conclusion isHXB2.gp120CL32 18 170 110
HXB2.gp120CL82 10 180 120 further supported by the viability of a series of HXB2
clones chimeric for gp120 regions derived from divergent
primary viruses from clades A–G (McKeating, unpub-
lished observation). Transfer of the primary gp120 regionto bind the V3 mAb 268-D. Only one of the l proteins, l31,
was found to bind the V2 mAb 12b, suggesting antigenic to HXB2 conferred the same pattern of cell tropism as
demonstrated for the original primary virus molecularvariation within the V2 region among the l clones. We
were able to detect the binding of mAb 2G12 to the clone(s) (Table 2). The V3 region has been reported to
be one of the determinants of T-cell tropism (De-Jong etsurface of all infected PBMC cultures by FACS analysis,
whereas we failed to detect binding of any of the other al., 1992); however, we found that l32, which was able
to infect both CEM and U937 cells, had the same V3mAbs to the infected cell surface (data not shown).
In order to assess whether gp120-gp41 association coding sequence as l clones 13 and 33, which were
unable to infect these cell lines. However, l clone 32differed between the l and gp120 chimeric viruses we
measured the amount of gp120 shed from the surface had a unique deletion in the V2 region at a position
previously reported to be associated with a switch fromof the infected PBMC cultures in the presence and
absence of sCD4 (at 20 mg/ml) at both 4 and 377 (Table NSI to SI phenotype (Schuitemaker et al., 1992; Groenink
et al., 1993), in addition to several unique substitutions5). No soluble gp120 was detected at 47; however,
gp120 was detected from all cultures at 377 in the pres- in the C1, V1, C2, C3, and C4 regions (Fig. 1). We (Palmer
et al., 1996) and others (Wang et al., 1995) have analyzedence of sCD4. Some variation was observed in the
amount of gp120 spontaneously released at 377; how- V2 length polymorphism in NSI and SI viruses obtained
from the same individuals over time and find no correla-ever, the chimeric viruses did not behave differently
from HXB2. Soluble CD4-induced shedding of gp120 tion between V2 length and tropism for MT-2 cells. Sta-
matos and Cheng-Mayer (1993) reported that a changefor both l and chimeric viruses was not appreciably
different, with a mean increase for the l clones of 1.7 at position 282 (N/D) within the C2 region was important
for the ability of HXB2 to replicate efficiently and induceand for the chimeric viruses of 1.8 (not including l13,
l82, and HXB2.CLl2, for which no gp120 was detected syncytia in the Hut-78 cell line. It is interesting to note
that l clone 32 encoded an aspartic acid (D) at thisin the absence of sCD4) (Table 5).
TABLE 3A
Neutralization of HXB2, l, and Chimeric Viruses
Neutralization with HIV/ human sera
Virus ID50 1 2 3 4 5 6 7 8 9 10 11
lCL2 15 / 0 / 0 0 0 0 0 0 0 0
lCL13 9 0 0 0 0 0 0 0 0 0 0 0
lCL31 17 0 0 0 0 0 0 0 0 0 0 0
lCL82 8 0 0 / 0 0 0 0 0 0 0 0
HXB2 25 / 0 / / / 0 / 0 / 0 /
HXB2.gp120 CL2 15 / 0 / / / 0 / 0 / 0 /
HXB2.gp120 CL13 20 / 0 / / / 0 / 0 0 0 /
HXB2.gp120 CL31 5 / 0 / 0 / 0 / 0 0 0 /
HXB2.gp120 CL82 15 / 0 / / / 0 / 0 / 0 0
Note. Human sera were used at a final concentration of 1/40. /, 90% inhibition of p24 antigen production in all three replicate wells; 0, no
reduction in p24 production in all replicate wells.
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TABLE 3B
Neutralization of HXB2, l, and Chimeric Viruses
Virus ID50 Neutralization with ligandsa
Ligand: 268-D 1.5e 2.1H 39.13g 2F5 2G12 10/76b 12b sCD4
Epitope: V3 CD4bs CD4bs CD4bs gp411 gp120 V2 V2
lCL2 11 0 0 0 0 / / 0 0 0
lCL13 15 0 0 0 0 0 / 0 0 0
lCL31 18 0 0 0 0 / / 0 0 0
lCL82 11 0 0 0 0 0 / 0 0 0
HXB2 25 0 / / / / / / / /
HXB2.pg120CL2 5 0 0 0 0 / / 0 0 0
HXB2.gp120CL13 15 0 0 0 0 / / 0 0 0
HXB2.gp120CL31 18 0 0 0 0 / / 0 0 0
HXB2.gp120CL82 20 0 0 0 0 / / 0 0 0
a All mAbs and sCD4 were used at a final concentration of 20 mg/ml.
position and virus derived from this clone exhibited the in agreement with those reported by Kabat and col-
leagues (1994) who demonstrated a positive correlationbroadest tropism to replicate in all cell lines tested (Tan
et al., 1993). between the replication of primary virus isolates and CD4
receptor expression levels in target cells. This correlationWe noted that equivalent amounts of p24 antigen were
produced in all infected PBMC cultures; furthermore, cul- was not observed for T-cell-adapted viruses. These data
suggest that primary viruses differ from T-cell-adaptedtures infected with virus derived from both l and chimeric
constructs resulted in similar levels of infectious extra- (HXB2) envelope glycoproteins in their interaction with
the surface of PBMC and of T-cell lines, whereby thecellular virus (ID50) (Table 1). In contrast, cultures infected
with either HXB2 or the gp160 chimeras failed to produce levels of cell surface CD4 may be rate-limiting for their
infection process.detectable levels of extracellular infectious virus. These
data confirm earlier observations of the poor correlation Moore and colleagues (1995) reported that primary
viruses, propagated in PBMC cultures, are relatively re-between levels of extracellular p24 antigen and infec-
tious titer (McKeating et al., 1990). Replacement of the sistant to neutralization by mAbs and human sera com-
pared to T-cell-line-adapted viruses. We were interestedgp120 region of HXB2 with that of a primary virus enabled
the virus to replicate more efficiently in PBMC. However, in determining if gp120 chimeras, possessing a constant
HXB2 gp41, showed altered sensitivity to neutralizationthe gp160 chimeras replicated poorly; one explanation
for this result is that other elements (tat, rev, nef, RRE) compared to the parental viruses. Our results clearly indi-
cate that the chimeric viruses were as sensitive as HXB2contained within the transferred fragment may be dis-
rupted. Cell-free infection experiments showed that the to neutralization by polyclonal human sera (Table 3B).
Since the envelope glycoprotein has been identified asgp120 chimeras replicated to a higher titer than HXB2 in
the Sup T1 cell line (Table 2B). It is of interest to note the major antigen responsible for the induction of neu-
tralizing antibodies, one interpretation of these data isthat this cell line expresses a high level of CD4 (mean
fluorescence intensity, MFI, of 714) compared to C8166 that gp41-specific antibodies constitute a substantial
component of the cross-neutralizing activity present incells (MFI 56) (data not shown). These observations are
TABLE 4
Reactivity of Ligands with Soluble Viral gp120/gp160
Bound ligand
Clone 268-D 1.5e 2.1H 39.13g 2G12 12b sCD4 HIV / pool
lCL2 / 0 / 0 / 0 // ///
lCL13 / 0 / 0 // 0 // //
lCL31 // / // // /// // // //
lCL32 // / // / /// 0 // ///
HXB2 0 / // // /// /// // ///
Note. Optical density (450 nm): 0, 0.10; /, 0.10–0.49; //, 0.50–0.99; ///, 1.00.
AID VY 7947 / 6a18$$$221 05-28-96 14:08:25 vira AP: Virology
457NEUTRALIZATION OF PRIMARY HIV-1 ENVELOPE CHIMERAS
TABLE 5 conserved between HXB2 and the l clones (data not
shown). Furthermore, mAbs specific for the CD4 b.s.Ability of sCD4 to Induce gp120 Dissociation from the Surface of
(1.5e, 2.1h, and 39.13g) were unable to neutralize virusesInfected PBMC Cultures
derived from either l or gp120.HXB2 clones, suggesting
Soluble gp120 (ng/ml) from 2 1 106 that the presentation of these epitopes was not altered in
infected PBMC the chimeric viruses (Table 3B). Furthermore, one gp120-
specific mAb, 2G12, recognizing a conformational epi-Clone 47 47 / sCD4 377 377 / sCD4
tope independent of the CD4 binding site (Buchacher et
lCL2 ud ud 12.0 21.0 al., 1994; Trkola et al., 1996), neutralized both l and chi-
lCL13 ud ud ud 10.5 meric viruses with similar efficiencies (endpoint neutral-
lCL31 ud ud 7.5 18.4 ization titers of 3–8 mg/ml) (data not shown). Sullivan and
lCL32 ud ud 7.0 14.3
colleagues (1995) reported an association between thelCL82 ud ud ud 14.8
ability of sCD4 to neutralize and its ability to induce dis-
HXB2 ud ud 8.4 18.5 sociation of gp120–gp41 for primary viruses. However,
HXB2.gp120CL2 ud ud ud 7.4
we found that sCD4 was able to induce gp120–gp41HXB2.gp120CL13 ud ud 9.2 23.0
dissociation from both l- and lgp120.HXB2-infectedHXB2.gp120CL31 ud ud 13.0 21.5
HXB2.gp120CL32 ud ud 14.5 25.0 cells, but was unable to neutralize cell-free virus at the
HXB2.gp120CL82 ud ud 20.1 25.8 highest concentration tested (20 mg/ml) (Tables 3 and 5).
The effect of antigenic variation on the sensitivity of
Note. ud, undetectable levels, i.e., 200 pg/ml.
the viruses to neutralization was tested by following the
ability of antibodies to bind to detergent-solubilized viral
gp120. The V3 mAb 268D was able to bind all the lhuman sera. A conserved neutralization epitope within
gp41 (aa ELDKWA) has been identified by a human mAb gp120 proteins with an affinity close to that for the MN
protein. However, this mAb failed to neutralize any of the2F5, which has been reported to cross-neutralize several
primary isolates within clade B (Muster et al., 1993; Bu- l or chimeric viruses despite its ability to neutralize the
MN isolate at a concentration of 0.5 mg/ml (data notchacher et al., 1994; Conley et al., 1994a; Kattinger, 1994).
Preliminary studies comparing HXB2 with a number of shown). These data are in agreement with recent obser-
vations suggesting that the V3 region may not be wellHXB2 chimeras expressing divergent primary gp120 pro-
teins show that all viruses are equally sensitive to neu- exposed on primary virion glycoproteins and may there-
fore not constitute the principal neutralization targettralization by sera from individuals infected with clade B
viruses (data not shown), further suggesting the impor- (Bou-Habib et al., 1995; Stamatatos and Cheng-Mayer,
1995). In contrast, antigenic variation was observed intance of conserved gp41 epitopes. This interpretation of
the data is further supported by the ability of some human the CD4 binding site such that clones 2 and 13 failed to
bind mAbs (1.5e, 39.13g) specific for epitopes overlap-sera to neutralize viruses of diverse origin, suggesting
conservation of epitopes among viruses of different sub- ping this region. However, clones 31 and 32 bound these
mAbs with an affinity close to that of HXB2, but weretypes. Since the gp41 region of the envelope glycoprotein
is more conserved than gp120 it constitutes an ideal resistant to neutralization. These data suggest that the
lack of neutralization of the l viruses by gp120-specifictarget for such antibodies.
Alternatively, primary envelope gp120 conformation antibodies may be partially explained by antigenic varia-
tion. However, some of the epitopes specific for thesemay be affected by association with the T-cell-adapted
HXB2 gp41 moiety, resulting in altered sensitivity to neu- ligands have been shown to be present in the solubilized
viral protein. Hence, the affinity of a mAb for solubletralization. However, HXB2 chimeras expressing MN and
SF-2 gp120 proteins exhibit the same pattern and sensi- monomeric gp120 does not correlate with its ability to
neutralize, in agreement with previous reports (Sullivantivity to neutralization by gp120-specific mAbs as the pa-
rental viruses (data not shown), arguing against altered et al., 1995; Sattentau et al., 1994). We therefore at-
tempted to measure the ability of the mAbs, used in thegp120 conformation in these chimeric viruses. Since the
majority of gp120-specific mAbs fails to neutralize pri- neutralization assays, to bind to the oligomeric envelope
surface of infected PBMC cultures. However, with themary viruses, such a direct comparison is more difficult.
We (Klasse et al., 1993) and others (Reitz et al., 1988; exception of 2G12, we failed to detect any cell surface
binding, and this result correlated with the ability of 2G12Wilson et al., 1990; Thali et al., 1994) reported that muta-
tion of residue 582 (Ala–Thr) in the gp41 domain of HXB2 to neutralize all viruses tested. Similarly, Sullivan and
colleagues (1995) reported that neutralization of virusresulted in a virus which was resistant to neutralization
by some antibodies specific for the CD4 binding site, by antibodies or sCD4 could be predicted by assays
measuring the binding of these ligands to the oligomericsupporting the hypothesis that gp120 conformation can
be modulated by amino acid changes in gp41. However, envelope glycoprotein complex. Consequently, it will be
important to study the immunogenicity of recombinantposition 582 (Ala) and the surrounding residues were
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Bou-Habib, D. C., Roderiquez, G., Oravecz, T., Berman, P. W., Lusso,oligomeric gp140 envelope proteins for their ability to
P., and Norcross, M. A. (1995). Cryptic nature of envelope V3 regioninduce antibodies capable of cross-neutralizing primary
epitopes protects primary monocytotropic human immnuodeficiecny
virus isolates (Earl et al., 1994). virus type 1 from antibody neutralization. J. Virol. 69, 6006–6013.
In summary, HXB2 and chimeric viruses expressing Buchacher, A., Predl, R., Strutzenberger, K., Steinfellner, W., Trkola, A.,
primary gp120 proteins were neutralized by polyclonal Purtscher, M., Gruber, G., Tauer, C., Steinndl, F., Jungbauer, A., and
Kattinger, H. (1994). Electrofusion and EBV transformation for PBLhuman sera. In contrast, the same chimeras were resis-
immortalization: Generation of human monoclonal antibodies againsttant to neutralization by sCD4 and the majority of gp120-
HIV-1 proteins. AIDS. Res. Hum. Retroviruses 10, 359–369.specific mAbs. Clearly, the chimeras behave more like
Burton, D. R., Pyati, J., Koduri, R., Sharp, S. J., Thornton, G. B., Parren,
the primary l viruses with respect to cell tropism, gp120– P. W. H. I., Sawyer, L. S., Hendry, R. M., Dunlop, N., Nara, P. L.,
gp41 association, and their relative resistance to neutral- Lamacchia, M., Garratty, E., Stiehm, E. R., Bryson, Y. J., Moore, J. P.,
Ho, D. D., and Barbas, C. F., III (1994). Efficient neutralization ofization by gp120-specific ligands. However, they behave
primary isolates of HIV-1 by a recombinant human monoclonal anti-more like HXB2 with respect to their neutralization by
body. Science 266, 1024–1027.polyclonal human sera. These data suggest that the es-
Cao, Y., Zhang, L. Q., Safrit, J., and Ho, D. D. (1995). Virologic and
sential properties which define a ‘‘primary virus oligomer’’ immunologic characterization of long-term survivors of human immu-
are defined by the gp120 region and that cross-reactive nodeficiency virus type 1 infection. N. Engl. J. Med. 332, 201–208.
Cheng-Mayer, C., Seto, D., Tateno, M., and Levy, J. A. (1988). Biologicneutralizing antibodies present in human sera may be
features of HIV-1 that correlate with virulence in the host. Sciencetargeted to epitopes in gp41.
240, 80–82.
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